Jamshedpur, August 1: Tata Main Hospital (TMH) has started Convalescent Plasma Therapy for treating COVID-19 positive patients. The hospital is also using Remdesivir and Favipiravir anti-viral medicines among COVID-19 patients under Emergency Use Authorisation. The Indian Council of Medical Research (ICMR) has given approval for the same.
The treatment involves taking plasma of patients who have recovered from COVID-19 as they carry antibodies against the viruses in their plasma.
As of now no medicine has been evolved for an effective treatment of COVID, but people who have recovered from COVID have antibodies — proteins the body uses to fight off infections — to the disease in their blood. The blood from people who have recovered is called convalescent plasma which is the liquid portion of the blood. Researchers have evolved that convalescent plasma can be given to people with severe COVID to boost their ability to fight the virus.
During a telephonic media interaction, Dr Rajan Choudhry, general manager, medical services, Tata Steel said, “We had felt the need to start providing plasma therapy to the COVID patients. Two donors have come forward to donate and their plasma will be used for the treatment of patients.”
The general manager informed that a total of 1203 patients have been treated at the hospital so far out of which 1069 patients are from East Sighbhum . In total 587 patients have been discharged after successful treatment. At present 448 patients are being treated at the hospital. In total 42 people have died at TMH of whom 34 were from Jamshedpur.
TMH has also tied up with Hotel Sonnet for using its premises as COVID care unit. Moreover, the hospital has converted GT hostel 4 and 3 as COVID care while work is on to augment 100 bed facilities at Tinplate Hospital and Jamshedpur Eye Hospital for coronavirus treatment.